Duvakitug not checked
Sanofi · SAR447189 · TEV-48574
FollowEvery change as it happens, and a Monday email
Trials
7 active
9 in total · 7 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
- How it’s given
- “Pharmaceutical form:Solution for Injection-Route of administration:SC injection”In the company’s words, NCT07184996 on ClinicalTrials.gov
- Tested for
- Ulcerative Colitis (3 trials), Crohn's Disease (3 trials), Crohn Disease, Colitis, Ulcerative, Hidradenitis
- Main trialPhase 3
- “This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include: The study duration may be up to 35 weeks with: * Screening period * 12-week Sub-Study 1 (Single-Arm Open-Label Feeder Induction) or Sub-Study 2 (Pivotal Induction) * 12-week Sub-Study 3 (Extended Induction for non-responders) * 45 days follow-up visit for participants who do not enroll into the maintenance study (EFC18359) The treatment…”In the company’s words, NCT07184996 on ClinicalTrials.gov
- Other names
- SAR447189 · TEV-48574
Other drugs for Ulcerative Colitis
- TofacitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- RisankizumabAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- ObefazimodAbivax S.A. · Phase 3
Coming up6
- 9 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 16 Jun 2028Phase 2 trial completes · ClinicalTrials.gov
- 8 Aug 2028Phase 1 trial completes · ClinicalTrials.gov
- 21 Sep 2028Phase 3 trial completes · ClinicalTrials.gov
- 14 May 2029Phase 3 trial completes · ClinicalTrials.gov
- 13 Aug 2029Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07812116
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 9 May 2028 | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 3Recruiting | 21 Sep 2028 | A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 3Recruiting | 14 May 2029 | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 3Recruiting | 13 Aug 2029 | A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 2Active, not recruiting | 5 Jan 2026 | A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease | |
| Phase 2Recruiting | 16 Jun 2028 | A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 1Not yet recruiting | 8 Aug 2028 | An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates | |
| Phase 2Terminated | 17 Jan 2022 | A Study to Test if TEV-48574 is Effective in Relieving Asthma | |
| Phase 2Completed | 12 Nov 2024 | A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026